Recommended Topic Related To:

Asmanex

"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...

Asmanex Twisthaler

Asmanex Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Asmanex Twisthaler (mometasone furoate) Inhalation Powder is used to prevent asthma attacks. It will not treat an asthma attack that has already begun. Asmanex is a steroid. Common side effects include dry or irritated throat, hoarseness or coughing.

Dosage of Asmanex for patients 12 years and older ranges from 220 mcg taken once daily to 440 mcg taken twice daily. The dose for children 4-11 years of age is 110 mcg taken once daily. The lowest dose that controls symptoms should be used. Asmanex may interact with ketoconazole (Nizoral). Other drugs may interact with Asmanex Twisthaler. Tell your doctor about all prescription and over-the-counter medications and supplements you use. During pregnancy, Asmanex Twisthaler should be used only when prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Our Asmanex Twisthaler (mometasone furoate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Asmanex in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • wheezing, choking, or other breathing problems after using this medication;
  • skin rash, bruising, severe tingling, numbness, pain, muscle weakness;
  • changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist); or
  • worsening asthma symptoms.

Less serious side effects may include:

  • headache;
  • increased sinus allergy symptoms (runny nose, stuffy nose, sinus pain), sore throat, nosebleed;
  • muscle or joint pain, back pain;
  • nausea, upset stomach, loss of appetite;
  • changes in menstrual periods;
  • tired feeling; or
  • hoarseness or deepened voice.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Asmanex (Mometasone Furoate) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Asmanex Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Precautions.

Dry or irritated throat, hoarseness or coughing may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if any of these unlikely but serious side effects occur: white patches on tongue/in mouth, signs of infection (such as fever, persistent sore throat), mental/mood changes (such as depression, trouble sleeping), vision problems (such as blurred vision), increased thirst/urination.

Rarely, this medication has caused severe (rarely fatal), sudden worsening of breathing problems/asthma (paradoxical bronchospasm). If you experience sudden wheezing, get medical help right away.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Asmanex (Mometasone Furoate)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Asmanex FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Systemic and local corticosteroid use may result in the following:

Clinical Studies Experience

The safety data described below reflect exposure to ASMANEX TWISTHALER (mometasone furoate) in 2380 patients with asthma exposed for 8 to 12 weeks and 627 patients with asthma exposed for 1 year in a total of 17 clinical trials.

In adult and adolescent patients 12 years of age and older, ASMANEX TWISTHALER (mometasone furoate) was studied in 10 placebo-controlled clinical trials of 8 to 12 weeks duration with a total of 1750 patients receiving ASMANEX TWISTHALER (mometasone furoate) . There were also 3 trials with a total of 475 patients receiving ASMANEX TWISTHALER (mometasone furoate) for 1 year. In the 8- to 12-week clinical trials, the population was 12 to 83 years of age, 38% males and 62% females, and 83% Caucasian, 8% black, 6% Hispanic, and 3% other race/ethnicity. Patients received ASMANEX TWISTHALER (mometasone furoate) 110 mcg twice daily (n=133), 220 mcg once daily in the morning (n=209), 220 mcg once daily in the evening (n=232), 220 mcg twice daily (n=433), 440 mcg once daily in the morning (n=419), 440 mcg once daily in the evening (n=250), or 440 mcg twice daily (n=74). In 3 long-term safety trials (two 9-month extensions of efficacy trials and one 52-week active-controlled safety trial), 475 patients with asthma (12 - 83 years of age, 44% males, 56% females, 87% Caucasian, 8% black, 4% Hispanic, and 1% other race/ethnicity) received various doses of ASMANEX TWISTHALER (mometasone furoate) for 1 year.

In pediatric patients 4 to 11 years of age, ASMANEX TWISTHALER (mometasone furoate) was studied in 3 placebo-controlled clinical trials of 12 weeks duration with a total of 630 patients receiving ASMANEX TWISTHALER (mometasone furoate) and a 52-week, active-controlled safety trial with a total of 152 patients receiving ASMANEX TWISTHALER (mometasone furoate) . In the 12-week clinical trials, the population was 4 to 11 years of age, 63% males and 37% females, and 67% Caucasian, 13% black, 17% Hispanic, and 3% other race/ethnicity. Patients received ASMANEX TWISTHALER (mometasone furoate) 110 mcg once daily in the evening (n=98), 110 mcg once daily in the morning (n=181), 110 mcg twice daily (n=179), or 220 mcg once daily in the morning (n=172). In the long-term active-controlled safety trial (n=152), patients with asthma (4 to 11 years of age, 60% males and 40% females, 84% Caucasian, 11% Black, and 5% Hispanic) received ASMANEX TWISTHALER (mometasone furoate) 110 mcg twice daily or 220 mcg once daily in the morning for 52 weeks.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults and Adolescents 12 Years of Age and Older

The safety results of the 10 trials that were 8 to 12 weeks in duration were pooled because patients with asthma in these studies were previously maintained on bronchodilators and/or inhaled corticosteroids. The safety results of the one 12-week clinical trial in patients with asthma previously treated with oral corticosteroids are presented separately.

In the pooled 8- to 12-week clinical trials, adverse reactions were reported in 70% of patients treated with ASMANEX TWISTHALER (mometasone furoate) (n=1750) compared to 65% of patients taking placebo (n=720). Table 2 displays the common adverse reactions ( ≥ 3% in any patient group receiving ASMANEX TWISTHALER (mometasone furoate) ) that occurred more frequently in patients treated with ASMANEX TWISTHALER (mometasone furoate) compared to patients treated with placebo.

TABLE 2: Adverse Reactions with ≥ 3% Incidence in 10 Controlled Clinical Trials with ASMANEX TWISTHALER (mometasone furoate) in Patients 12 Years of Age and Older Previously on Bronchodilators and/or Inhaled Corticosteroids

Adverse Reaction (%) of Patients
ASMANEX TWISTHALER Placebo
(n=720)
220 mcg
twice daily
(n=433)
440 mcg
once daily
(n=497)
220 mcg
once daily in the evening
(n=232)
Headache 22 17 20 20
Allergic Rhinitis 15 11 14 13
Pharyngitis 11 8 13 7
Upper Respiratory Infection 10 8 15 7
Sinusitis 6 6 5 5
Candidiasis, oral 6 4 4 2
Dysmenorrhea* 9 4 4 4
Musculoskeletal Pain 8 4 4 5
Back Pain 6 3 3 4
Dyspepsia 5 3 3 3
Myalgia 3 2 3 2
Abdominal Pain 3 2 3 2
Nausea 3 1 3 2
Average Duration of Exposure (Days) 81 70 80 62
* Percentages are based on the number of female patients.

The following other adverse reactions occurred in these clinical trials with an incidence of at least 1% but less than 3% and were more common on ASMANEX TWISTHALER therapy than on placebo:

Body as a Whole: fatigue, flu-like symptoms, pain

Gastrointestinal: gastroenteritis, vomiting, anorexia

Hearing, Vestibular: earache

Resistance Mechanism: infection

Respiratory: dysphonia, epistaxis, nasal irritation, respiratory disorder, throat dry

In the 12-week trial in adult asthmatics who previously required oral corticosteroids, the effects of ASMANEX TWISTHALER (mometasone furoate) therapy administered as two 220mcg inhalations twice daily (n=46) were compared with those of placebo (n=43). Adverse reactions, whether considered drug-related or not by the investigators, reported in more than 3 patients in the ASMANEX TWISTHALER (mometasone furoate) treatment group, and which occurred more frequently than in placebo were (ASMANEX TWISTHALER (mometasone furoate) % vs. placebo %): musculoskeletal pain (22% vs. 14%), oral candidiasis (22% vs. 9%), sinusitis (22% vs. 19%), allergic rhinitis (20% vs. 5%), upper respiratory infection (15% vs. 14%), arthralgia (13% vs. 7%), fatigue (13% vs. 2%), depression (11% vs. 0%), and sinus congestion (9% vs. 0%). In considering these data, an increased duration of exposure for patients on ASMANEX TWISTHALER (mometasone furoate) treatment (77 days vs. 58 days on placebo) should be taken into account.

Long-Term Clinical Trials Experience - 12 Years of Age and Older

In 3 long-term safety trials, 475 patients with asthma 12 years of age and older were treated with ASMANEX TWISTHALER (mometasone furoate) 220 mcg twice daily (n=60), 220 mcg once daily in the morning (n=41), 220 mcg once daily in the evening (n=40), 440 mcg once daily in the morning (n=44), 440 once daily in the evening (n=41), 440 mcg twice daily (n=62), 880 mcg once daily (n=59), or at variable doses (n=128) for 52 weeks. The safety profile of ASMANEX TWISTHALER (mometasone furoate) in the 52-week trials was similar to the findings in the 8- to 12-week clinical trials. In patients previously on inhaled corticosteroids, cataracts were reported in 3 patients (0.9%) treated with ASMANEX TWISTHALER (mometasone furoate) , compared to 1 patient (1.7%) treated with the active comparator medication. Increased ocular pressure at the end of the study was observed in 2 patients, both on ASMANEX TWISTHALER (mometasone furoate) 880 mcg once daily in the morning. Oral candidiasis, dysphonia, and dysmenorrhea were seen at a higher frequency with long-term administration than in the 8- to 12-week trials.

Pediatric Patients 4 to 11 Years of Age

In the three 12-week clinical trials in pediatric patients 4 to 11 years of age, patients with asthma were previously maintained on bronchodilators and/or inhaled corticosteroids. The safety results from 1 trial are described in Table 3 for ASMANEX TWISTHALER (mometasone furoate) 110 mcg once daily in the evening. The safety results from the other 2 trials showed similar findings.

Overall adverse reactions were reported with approximately the same frequency by patients treated with ASMANEX TWISTHALER (mometasone furoate) and those receiving placebo. Table 3 displays the common adverse reactions ( ≥ 2% in any patient group receiving ASMANEX TWISTHALER (mometasone furoate) ) that occurred more frequently in patients 4 to 11 years of age treated with ASMANEX TWISTHALER (mometasone furoate) compared with placebo-treated patients.

TABLE 3: Adverse Reactions with ≥ 2% Incidence in a 12-Week Study with ASMANEX TWISTHALER (mometasone furoate) in Patients 4 to 11 Years of Age Previously on Bronchodilators and/or Inhaled Corticosteroids

Adverse Reaction (%) of Patients
ASMANEX TWISTHALER
110 mcg once
daily in the
evening (n=98)
Placebo
(n=99)
Fever 7 5
Allergic Rhinitis 4 3
Abdominal Pain 6 2
Vomiting 3 2
Urinary Tract Infection 2 1
Bruise 2 0
Average Duration of Exposure (Days) 72 68

Long-Term Clinical Trials Experience in Children 4 to 11 Years of Age

In a 52-week, active-controlled, long-term safety trial, 152 patients with asthma 4 to 11 years of age were treated with ASMANEX TWISTHALER (mometasone furoate) 110 mcg twice daily (n=74) or 220 mcg once daily (n=78). The safety profile for ASMANEX TWISTHALER (mometasone furoate) in the 52-week trial was similar to the findings in the 12-week clinical trials.

Post marketing Experience

The following adverse reactions have been reported during post-approval use of ASMANEX TWISTHALER (mometasone furoate) . Because they are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Immediate and delayed hypersensitivity reactions including rash, pruritus, angioedema and anaphylactic reaction. [see WARNINGS AND PRECAUTIONS and CONTRAINDICATIONS]

Respiratory, Thoracic and Mediastinal Disorders: Asthma aggravation, which may include cough, dyspnea, wheezing and bronchospasm.

Read the entire FDA prescribing information for Asmanex (Mometasone Furoate) »

A A A

Asmanex Twisthaler - User Reviews

Asmanex Twisthaler User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Asmanex Twisthaler sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Allergies & Asthma

Improve treatments & prevent attacks.


NIH talks about Ebola on WebMD